A multicentre, double-blind, active controlled trial to evaluate the clinical effects of immediate release paroxetine and controlled release paroxetine in the treatment of major depression.
Latest Information Update: 18 Jul 2023
Price :
$35 *
At a glance
- Drugs Paroxetine (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 07 Jun 2010 Primary endpoint 'Hamilton Depression Rating Scale' has been met.
- 07 Jun 2010 Results have been presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
- 26 Nov 2007 Status changed from recruiting to completed.